1. Home
  2. KALV vs CPF Comparison

KALV vs CPF Comparison

Compare KALV & CPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$17.04

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Logo Central Pacific Financial Corp New

CPF

Central Pacific Financial Corp New

HOLD

Current Price

$30.26

Market Cap

811.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
CPF
Founded
N/A
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
811.3M
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
KALV
CPF
Price
$17.04
$30.26
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$30.00
$35.50
AVG Volume (30 Days)
761.7K
153.2K
Earning Date
05-09-2026
04-22-2026
Dividend Yield
N/A
3.78%
EPS Growth
N/A
45.18
EPS
N/A
2.86
Revenue
$50,000,000.00
$51,817,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.37
P/E Ratio
N/A
$10.72
Revenue Growth
495.66
33.81
52 Week Low
$9.83
$23.16
52 Week High
$19.00
$35.01

Technical Indicators

Market Signals
Indicator
KALV
CPF
Relative Strength Index (RSI) 55.56 32.39
Support Level $14.59 $27.98
Resistance Level $17.30 $31.50
Average True Range (ATR) 1.10 0.78
MACD -0.05 -0.12
Stochastic Oscillator 53.88 7.20

Price Performance

Historical Comparison
KALV
CPF

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.

Share on Social Networks: